And The UK's First 'Innovation Passport' Goes To... MSD's Rare Disease Drug Belzutifan
Regulator Invites More Applications For New Pathway
Executive Summary
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
You may also be interested in...
MSD & Kyowa Question NICE’s Processes After English Funding Rejected For Rare Disease Drugs
MSD and Kyowa Kirin have separately criticized England’s HTA body, NICE, for assessing their respective rare disease medicines Welireg and Crysvita using its standard appraisal pathway. Both medicines were provisionally rejected for reimbursement.
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
Scotland First To OK Reimbursement For MSD's Welireg, But Situation In England Remains Unclear
The SMC, the Scottish health technology assessment body, has approved reimbursement for the first drug to win an innovation passport from the UK regulator.